PT  - JOURNAL ARTICLE
AU  - Nho, Kwangsik
AU  - Risacher, Shannon L.
AU  - Apostolova, Liana
AU  - Bice, Paula J.
AU  - Brosch, Jared
AU  - Deardorff, Rachael
AU  - Faber, Kelley
AU  - Farlow, Martin R.
AU  - Foroud, Tatiana
AU  - Gao, Sujuan
AU  - Rosewood, Thea
AU  - Kim, Jun Pyo
AU  - Nudelman, Kelly
AU  - Yu, Meichen
AU  - Aisen, Paul
AU  - Sperling, Reisa
AU  - Hooli, Basavaraj
AU  - Shcherbinin, Sergey
AU  - Svaldi, Diana
AU  - Jack, Clifford R.
AU  - Jagust, William J.
AU  - Landau, Susan
AU  - Vasanthakumar, Aparna
AU  - Waring, Jeffrey F.
AU  - Doré, Vincent
AU  - Laws, Simon M.
AU  - Masters, Colin L.
AU  - Porter, Tenielle
AU  - Rowe, Christopher C.
AU  - Villemagne, Victor L
AU  - Dumitrescu, Logan
AU  - Hohman, Timothy J.
AU  - Libby, Julia B.
AU  - Mormino, Elizabeth
AU  - Buckley, Rachel F.
AU  - Johnson, Keith
AU  - Yang, Hyun-Sik
AU  - Petersen, Ronald C.
AU  - Ramanan, Vijay K.
AU  - Vemuri, Prashanthi
AU  - Cohen, Ann D.
AU  - Fan, Kang-Hsien
AU  - Kamboh, M. Ilyas
AU  - Lopez, Oscar L.
AU  - Bennett, David A.
AU  - Ali, Muhammad
AU  - Benzinger, Tammie
AU  - Cruchaga, Carlos
AU  - Hobbs, Diana
AU  - De Jager, Philip L.
AU  - Fujita, Masashi
AU  - Jadhav, Vaishnavi
AU  - Lamb, Bruce T.
AU  - Tsai, Andy P.
AU  - Castanho, Isabel
AU  - Mill, Jonathan
AU  - Weiner, Michael W.
AU - Alzheimer’s Disease Neuroimaging Initiative (ADNI)
AU - the Alzheimer’s Disease Neuroimaging Initiative – Department of Defense
AU - the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study (A4 Study)
AU - Australian Imaging, Biomarker & Lifestyle Study (AIBL)
AU  - Saykin, Andrew J.
TI  - Novel <em>CYP1B1-RMDN2</em> Alzheimer’s disease locus identified by genome-wide association analysis of cerebral tau deposition on PET
AID  - 10.1101/2023.02.27.23286048
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.27.23286048
4099  - http://medrxiv.org/content/early/2023/03/22/2023.02.27.23286048.short
4100  - http://medrxiv.org/content/early/2023/03/22/2023.02.27.23286048.full
AB  - Determining the genetic architecture of Alzheimer’s disease (AD) pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we performed a genome-wide association study of cortical tau quantified by positron emission tomography in 3,136 participants from 12 independent studies. The CYP1B1-RMDN2 locus was associated with tau deposition. The most significant signal was at rs2113389, which explained 4.3% of the variation in cortical tau, while APOE4 rs429358 accounted for 3.6%. rs2113389 was associated with higher tau and faster cognitive decline. Additive effects, but no interactions, were observed between rs2113389 and diagnosis, APOE4, and Aβ positivity. CYP1B1 expression was upregulated in AD. rs2113389 was associated with higher CYP1B1 expression and methylation levels. Mouse model studies provided additional functional evidence for a relationship between CYP1B1 and tau deposition but not Aβ. These results may provide insight into the genetic basis of cerebral tau and novel pathways for therapeutic development in AD.Competing Interest StatementDeclaration of interests Dr. Apostolova received grant or other financial support from the National Institutes of Health (NIH), Alzheimers Association, AVID Pharmaceuticals, Life Molecular Imaging, Roche Diagnostics, and Eli Lilly. In addition, she has received consulting fees from Biogen, Two Labs, IQIVA, Florida Department of Health, Genentech, NIH Biobank, Eli Lilly, GE Healthcare, Eisai, and Roche Diagnostics. She has also received payment or honoraria from American Academy of Neurology, MillerMed, National Alzheimers Coordinating Center CME, CME Institute, APhA, Purdue University, Mayo Clinic, MJH Physician Education Resource, and Ohio State University. She received support for travel from the Alzheimers Association. She has served on Data Safety and Monitoring or Advisory Boards for IQVIA, UAB Nathan Schock Center, New Mexico Exploratory ADRC, and NIA R01 AG061111. She has a leadership role in multiple committees, including the Medical Science Council of the Alzheimers Association Greater Indiana Chapter, the Alzheimers Association Science Program Committee, and the FDA PCNS Advisory Committee. Finally, Dr. Apostolova holds stock in Cassava Neurosciences and Golden Seeds. Dr. Foroud receives support from multiple NIH grants (U24 NS095871, U24 AG021886, U24 AG056270, U01 AA026103, U10 AA008401, P30 AG010133, R01 AG019771, U01 AG032984, P30 AR072581, U01 AG057195, UL1 TR002529, U19 AG063911; U19 AG063744, U19 AG068054, R01 AG069453, U54 CA196519, R01 AG061146, R01 AG073267, R01 AG074971, U19 AG071754, R01 AG055444, R01 AG070349, U19 AG024904, R01 AG076634, U19 AG079774, U54 CA280897, U19 NS120384); the Michael J. Fox Foundation (MJFF001948); Cohen Veterans Biosciences; The Parkinsons Disease Foundation; Childrens Tumor Foundation; Broad Institute; Lumind Foundation; and Gates Venture (0432-06-120975). Dr. Jagust has served as a consultant for Biogen, Eisai, Lilly, and Bioclinica. He has an equity interest in Optoceuticals. Aparna Vasanthakumar and Jeffrey F. Waring are employees of AbbVie and may own AbbVie stock. Dr. Hohman receives support from multiple NIH grants (U24-AG074855, P20-AG068082, R01-AG061518, R01-AG059716, R01-AG074012, RF1-AG059869). He also sits on the advisory board for Vivid Genomics and is a Senior Associate Editor for Alzheimers and Dementia: Translational Research and Clinical Intervention. Hyun-Sik Yang received personal fees (honorarium) from Genentech, Inc outside the submitted work. Dr. Vemuri receives funding support from the NIH. Dr. Cruchaga has received research support from: GSK and EISAI. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Dr. Cruchaga is a member of the advisory board of Vivid Genomics and Circular Genomics. Dr. Saykin receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U19 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); NIH NHLBI (MESA Observational Study Monitoring Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). The other authors declare no conflict of interest.Funding StatementData collection and sharing for this project was funded by the Alzheimers Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U19 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). Additional support for data collection and/or analysis was provided by R01 LM012535, R03 AG054936, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, R01 LM013463, R01 AG068193, U01 AG068057, U01 AG072177, R01 LM011360, DOD W81XWH-14-2-0151, NIGMS P50GM115318, NCATS UL1 TR001108, K01 AG049050, R01 AG061788, R01 AG052446, R01 AG052521, RF1 AG052525, P30 AG066468, P01 AG025204, and Donors Cure Foundation. The AIBL study has received partial financial support from the Alzheimers Association (US), the Alzheimers Drug Discovery Foundation, an Anonymous foundation (a philanthropic foundation based in the US; one of the conditions of the funding is maintenance of anonymity), the Science and Industry Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Governments Operational Infrastructure Support program, the Australian Alzheimers Research Foundation, the National Health and Medical Research Council (NHMRC) Australia, and The Yulgilbar Foundation. Numerous commercial interactions have supported data collection and analyses. In-kind support has also been provided by Sir Charles Gairdner Hospital, Cogstate Ltd., Hollywood Private Hospital, The University of Melbourne, and St Vincents Hospital. Additional support for data collection and/or analysis was provided by NHMRC grants (GNT1161706, GNT1191535) awarded to SML. Support for the Harvard Aging Brain Study (HABS) was provided by NIH-NIA Program Project P01-AG036694. NIH-NIA K23AG062750. The A4 study was funded by the National Institute on Aging (grants U19AG010483 and R01AG063689, Eli Lilly and Co, and several philanthropic organizations (NCT02008357). The Mayo Clinic Study of Aging (MCSA) funding includes NIH grants U01 AG006786, R01 NS097495, R01 AG56366, P50 AG016574, P30 AG062677, R37 AG011378, R01 AG041851, R01 AG034676, C06 RR018898. The GHR Foundation, the Alexander Family Alzheimers Disease Research Professorship of the Mayo Clinic, the Alzheimers Association, the Mayo Foundation for Medical Education and Research, the Liston Award, the Elsie and Marvin Dekelboum Family Foundation, the Schuler Foundation. National Centralized Repository for Alzheimers Disease and Related Dementias (NCRAD): U24AG021886. This work was supported by grants from the National Institutes of Health, R01AG044546, P01AG003991, RF1AG053303, RF1AG058501, U01AG058922, and the Chan Zuckerberg Initiative (CZI), the Michael J. Fox Foundation, the Department of Defense (LI- W81XWH2010849) and the Alzheimers Association Zenith Fellows Award (ZEN-22-848604). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, P01AG03991, and P01AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. Additional funding from NIH National Institute on Aging includes R01 AG059716, R01 AG061518, R01 AG034570, and P30 AG066468. The University of Pittsburgh School of Public Health, Department of Genetics includes R01 AG064877 and P30 AG066468. California-Lawrence Berkeley National Laboratory includes R01 AG034570 and R01 AG062542. The rTg4510 and J20 mouse work was funded in part through the Medical Research Council (MRC) Proximity to Discovery: Industry Engagement Fund (Precision Medicine Exeter Innovation Platform reference MC_PC_14127), an MRC Clinical Infrastructure award (MR/M008924/1), a Wellcome Trust Multi-User Equipment Award (WT101650MA) and through a research grant from Alzheimers Research UK (ARUK-PG2018B-016).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained for all participants, and studies were approved by the relevant institutional review boards (IRB) at each site and for each cohort. Overall, analysis and integration of deidentified data was approved by Indiana University IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are either available online at adni.loni.usc.edu https://ida.loni.usc.edu/collaboration/access/appLicense.jsp;jsessionid=2CC9FA6681E2924181B892706F917FEA or are available upon reasonable request from the authors. https://adni.loni.usc.edu https://ida.loni.usc.edu/collaboration/access/appLicense.jsp;jsessionid=2CC9FA6681E2924181B892706F917FEA https://www.synapse.org/#!Synapse:syn17115987 https://www.synapse.org/#!Synapse:syn31512863 ADAlzheimer’s diseaseGWASgenome-wide association studySNPsingle nucleotide polymorphismCSFcerebrospinal fluidPETpositron emission tomographyAPOEapolipoprotein EADNIAlzheimer’s Disease Neuroimaging InitiativeADNI-DoDADNI-Department of DefenseIMASIndiana Memory and Aging StudyeQTLexpression quantitative trait lociSUVRstandard uptake value ratioFWHMFull Width at Half MaximumROIregion of interestHRCHaplotype Reference ConsortiumMAFminor allele frequencyLASSOLeast Absolute Shrinkage and Selection OperatorCEUUtah residents with Northern and Western European ancestry from the CEPH collectionTSIToscani in ItaliaMDSmultidimensional scalingCNCognitively normal older adultsMCIMild cognitive impairmentRMDN2Regulator of Microtubule Dynamics 2CYP1B1Cytochrome P450 Family 1 Subfamily B Member 1